Survivin is a multitasking protein that can inhibit cell death and that is essential for mitosis. Due to these prosurvival activities and the correlation of its expression with tumor resistance to conventional cancer treatments, survivin has received much attention scientifically and as a potential oncotherapeutic target. Nevertheless, many questions regarding its exact role at the molecular level remain to be elucidated. In this study we ask whether the extreme C- and NH2 termini of survivin are required for it to carry out its cytoprotective and mitotic duties. When assayed for their ability to act as a cytoprotectant, both survivin11-120 and survivin11-142 were able to protect cells against TRAIL-mediated apoptosis, but when challenged with irradiation cells expressing survivin11-142 had no survival advantage. During mitosis, however, removing the NH2 terminal 10 amino acids (survivin11-142) had no apparent effect but truncating 22 amino acids from the C-terminus (survivin11-120) prevented survivin from transferring to the midzone microtubules during anaphase. Collectively the data herein presented suggest that the C-terminus is required for cell division, and that the NH2 terminus is dispensable for apoptosis and mitosis but required for protection from irradiation.

Introduction

Survivin is a prosurvival factor that inhibits cell death and is essential for mitosis. It is overexpressed in all cancers1 and its abundance correlates with tumor resistance to conventional therapies including chemo and radiation.2,4 Thus it has received much attention scientifically and as a potential oncotherapeutic target.

The crystal structure of human survivin has been solved in 2 forms, as a homodimer,5,6 and in complex with its mitotic partners, borealin and INCENP.7 These structural analyses have revealed that survivin is essentially a globular protein with an outward projecting C-terminal α helix of approximately 40 amino acids (Fig. 1A). It homodimerises via a short linker positioned centrally between the globular domain and the extended helical tail, and engages leucine 6 and tryptophan 10 from the NH2 terminus at this interface to secure the interaction.5,6,8 The central linker also contains a nuclear export signal (NES), which actively shuttles survivin into the cytoplasm in a CRM1 dependent manner.9-11 If the NES is mutated or survivin is artificially relocated to the nucleus, it no longer protects cells from apoptosis or irradiation.9 This loss of cytoprotection might be due to more rapid turnover of survivin in the nucleus.12 However, there is also evidence that nuclear survivin may play a protective role by reducing DNA damage or facilitating DNA repair as cells expressing survivin have fewer DNA lesions when compared with control cells.13

Reconciling this apparent paradox, when cells are exposed to irradiation (IR), survivin relocates from the cytoplasm to the nucleus.13,14 Given that forced nuclear relocation eliminates cytoprotection, these data suggest that survivin may be post-translationally modified when retained in the nucleus post-IR, indeed acetylation at K129, has been implicated in nuclear enrichment.15

During mitosis survivin is a chromosomal passenger protein (CPP), which operates in the chromosomal passenger complex (CPC) with aurora-B, borealin and INCENP. The CPC facilitates the correction of malorientated chromosomes during prometaphase congression, and the execution of cytokinesis.16,17 When bound to its mitotic partners, the C-terminus becomes part of a 3 helix bundle comprised of the NH2 terminus of borealin (see Fig. 1B), and the coiled coil region of INCENP.7 Survivin targets the CPC to the centromere, via two acidic residues D71,D72, in the BIR domain, which bind to threonine 3 of Histone H3, when it has been phosphorylated by the mitotic kinase, haspin.18

The aim of this study was to determine whether the C- and NH2-termini of survivin are required for its known roles in cytoprotection and/or mitosis.

© Sally P Wheatley
*Correspondence to: Sally P Wheatley; Email: sally.wheatley@nottingham.ac.uk
Submitted: 10/17/2014; Accepted: 10/20/2014
http://dx.doi.org/10.4161/15384101.2014.979680
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
Results and Discussion

In this report whether the extreme C- and NH2-terminal ends of survivin are required for its ability to inhibit cell death, or for its essential function during mitosis was investigated. To do this 2 truncation mutants were generated, one in which the C-terminal 22 amino acids were removed (see Figs. 1A and B), referred to as survivin1–120, and the other lacking the first 10 amino acids, survivin11–142. Expression constructs encoding these truncations were transfected into HeLa cells and cell lines stably expressing these forms were generated. GFP and survivin-GFP expressing cells were used as controls, see.\textsuperscript{19} Immunoblotting was used to verify the size of ectopic proteins and compare their levels of expression (Fig. 1C). Fluorescence imaging revealed that 90% of all cells were expressing these constructs (data not shown), and like wild type (WT) both

2 truncation mutants were generated, one in which the C-terminal 22 amino acids were removed (see Figs. 1A and B), referred to as survivin1–120, and the other lacking the first 10 amino acids, survivin11–142. Expression constructs encoding these truncations were transfected into HeLa cells and cell lines stably expressing these forms were generated. GFP and survivin-GFP expressing cells were used as controls, see.\textsuperscript{19} Immunoblotting was used to verify the size of ectopic proteins and compare their levels of expression (Fig. 1C). Fluorescence imaging revealed that 90% of all cells were expressing these constructs (data not shown), and like wild type (WT) both...
Survivin terminal truncations can inhibit apoptosis

To test whether these truncation mutants could protect cells against apoptosis, asynchronous cells expressing GFP, or the GFP tagged survivin forms indicated, were treated with TRAIL for 0, 60, or 90 minutes, whole cell lysates prepared, and apoptosis assessed using a caspase-3 tetrapeptide cleavage assay (Fig. 1E). In this assay lysates from cells overexpressing WT reduced caspase-3 activity compared with cells expressing GFP alone, as expected. Lysates prepared from cells expressing survivin1–120 and survivin11–142 were also able to protect cells against this apoptotic challenge, demonstrating that neither end of the protein is required to inhibit TRAIL-mediated apoptosis.

NH2 truncation eliminates protection from X-irradiation

Next to test the ability of survivin mutants to protect cells against a second death-signaling pathway, cells were exposed to increasing doses of X-rays (0, 2.5 and 5 Gy). Survival was monitored using a clonogenic assay in which colonies of 50 cells or more were counted 7 d post-treatment, and plotted on a logarithmic scale as the "surviving fraction." As shown in Figure 1F, when compared to control cells expressing only GFP, WT protected cells against this challenge. Surprisingly, despite effectively protecting cells against TRAIL, cells expressing survivin11–142 exhibited the same sensitivity to IR as GFP control cells, while survivin1–120 conferred a similar level of protection against this challenge, demonstrating that neither end of the protein is required to inhibit TRAIL-mediated apoptosis.

Localization of survivin truncations during mitosis

To investigate whether the ends of survivin are required for cell division the localization of these truncation mutants during mitosis was examined. Survivin has a very distinct pattern of localization during mitosis.24, 25 It is centromeric until the metaphase-anaphase transition, after which it transfers to the centromeric anaphase spindle, decorates the equatorial cortex at the site where the cell will form the cleavage furrow, and finally it is discarded from the cell during cytokinesis via midbody externalisation (Fig. 2A). Interestingly, although the C-terminal truncation, survivin1–120 localized to the centromeres during early mitosis, it was not specifically confined to these foci, instead it was distributed all along the chromosome arms (Fig. 2B, upper panel). Most strikingly instead of transferring to the midzone during anaphase, survivin1–120 remained associated with the chromosome arms and appeared to become enriched at the ends of the separating chromosomes (Fig. 2B, middle panels). The NH2-terminal truncation, survivin11–142 also mislocalized but in contrast to survivin1–120, it was simply found diffusely localized at all stages (Fig. 2C). Neither truncation concentrated at the midbody (Figs. 2B and 2C, lower panels). The inability of these mutants to localize to the central anaphase spindle was not due to a defect in this structure itself as intact midzone microtubules were clearly evident in fixed anaphase cells immunoprobed with anti-tubulin antibodies (Fig. 2D). We also noted that the chromosomal localization of survivin1–120 witnessed in live cells was compromised when cells were fixed, compare middle panels in Figures 2B and D.

The competence of these versions of survivin to correct maloriented chromosomes was then assessed using an error correction assay. Briefly, cells were arrested in mitosis with monopolar spindles and syntetically attached chromosomes using the Eg5 inhibitor dimethylastraon (DMA), harvested by mitotic shake-off, then released for 120 minutes before fixing and immunoprobing with anti-tubulin antibodies. The percentage of cells in each mitotic stage was then assessed by fluorescence microscopy and quantified (Fig. 2E). As judged by the percentage of cells persisting in prometaphase at 120 minutes (35%), survivin1–120 was less efficient at correcting maloriented chromosomes compared to either WT or survivin11–142 which both had a majority (approx. 80%) of their populations in cytokinesis. In addition we noted that while only 10.9% (N = 92; WT) and 10% (N = 70; survivin11–142) cells exhibited abnormalities during mitotic exit, 92.3% (N = 26) of the survivin1–120 population were aberrant, clearly demonstrating that this form causes genomic instability during mitosis.

In all cells examined in Figure 2 the native protein as well as the ectopic form was present. Thus to ascertain whether the localization of the ectopic forms was influenced by the endogenous protein the distribution of the siRNA resistant truncation mutants was re-examined after depletion of the native protein. Surprisingly, although the localization of survivin1–120 remained unchanged (Fig. 3A), removing native survivin enabled survivin11–142 to localize normally, gaining access to the centromeres and the midzone during prometaphase and anaphase respectively (Fig. 3B). Removal of endogenous

survivin1–120 and survivin11–142 were predominantly localized within the cytoplasm of interphase cells. (Fig. 1D)
survivin and resistance of the ectopic forms to siRNA was verified by immunoblotting (Fig. 3C). Mislocalisation only in the presence of the endogenous protein suggests competition rather than interaction and raises the question as to whether the NH2 terminus is really involved in survivin dimerization, as has been suggested for L6 and W10.5 Note also that removal of the endogenous protein from survivin 11–142 cells does not impact on the outcome of the TRAIL assay, survivin11–142 remains protective in its absence (data not shown). On the flipside, loss of this end is not expected to interfere with the essential mitotic borealin-INCENP helix interaction7 (see Fig. 1B). These experiments suggest that the NH2 terminus is dispensable for mitosis, but that the C-terminus facilitates centromere targeting and is required for transfer to the central spindle during anaphase, data that concur with.26

Figure 2. Survivin truncations mislocalise during mitosis. (A–C) Exponentially growing HeLa cells expressing (A) survivin-GFP (WT); (B) survivin1–120-GFP and (C) survivin11–142-GFP as indicated, were stained with NucBlue and imaged live. (D) Anaphase cells were fixed with formaldehyde and immunoprobed with anti-tubulin antibodies to show the integrity of the central spindle in the different lines. Scale bars 5 μm. (E) Analysis of mitotic stages of cells 120 minutes post-release from DMA-induced mitotic arrest.

**Truncation of the C-terminus inhibits mitosis.**
To determine whether these mutants can support mitosis alone, cell proliferation was monitored at 0, 48 and 72h post-siRNA. As shown in Figure 3D survivin depletion inhibited proliferation of cells expressing GFP alone (control), while those expressing the siRNA resistant WT form, continued to grow. By contrast, although populations of both survivin1–120 and survivin11–142 expressing cells expanded, they did not rescue
proliferation as efficiently as WT suggesting a partial, but incomplete rescue. Next the DMA arrest and release assay was repeated in cell populations that had been depleted of endogenous survivin for 48h, and their ability to exit mitosis analyzed by fluorescence imaging. As shown in Figure 3E, while the majority of WT and survivin 11-142 expressing cells were either completing a normal cytokinetic event, or were in G1 (mononucleated) 2h post-release from DMA, the survivin 1-120 experienced many difficulties, which resulted in 14% with multiple nuclei, 43% undergoing apoptosis.

As survivin 1-120 and survivin 11-142 clearly were different in their mitotic competency, yet the proliferation assay in Figure 3D suggested that they were equally effective at (partially) restoring cell growth, the siRNA experiment was extended to a clonogenic analysis to assess survival more specifically. Briefly, cells that had been exposed to control or survivin specific siRNA for 72 h were seeded at low density onto live imaging chambers and petri dishes. The number of colonies that formed in the survivin siRNA treated populations was counted and expressed as a percentage of the control siRNA treated population (top left corner of each panel, Fig. 4A). In addition, fluorescence imaging of colonies seeded
onto live imaging chambers revealed that the GFP control cells were unable to form viable colonies (Fig. 4A), while those expressing WT survivin grew into uniform colonies with cells of regular size. This assay clearly demonstrated that survivin11–142 expressing cells form a similar number of highly regular exponentially growing colonies to WT, however, consistent with the mitotic defects observed in previous experiments, the colonies that developed from cells expressing survivin1–120 contained many binucleated and multinucleated cells (Fig. 4B) further confirming that mitosis and cytokinesis was impaired in this population. The average number of cells in each colony was also counted (Fig. 4C), and was found to be highest in the WT (72.3±14.6) population and lowest and most variable in the population expressing survivin1–120 (42.4±20.8). Interestingly, survivin11–142 expressing colonies had on average 58.8±6.6 cells, suggesting that the less efficient rescue observed for this cell line in the proliferation assay may be due to a reduced rate of cell growth, rather than any reduction in viability.

Truncation of the C-terminus disrupts interaction with borealin

The observation that survivin1–120 expressing cells fail to divide is consistent with previous studies that have reported that the C-terminal helix is responsible for binding to borealin (see Fig. 1B). Indeed, in a parallel paper, we recently reported that substitution of a lysine at position 129, for a glutamic acid, K129E, is sufficient to inhibit survivin from interacting with borealin.27 Thus to confirm that C-terminal truncation abrogates interaction with borealin, an immunoprecipitation assay was performed with each of the cell lines. Immunoblotting analysis after immunoprecipitation with anti-GFP antibodies revealed that borealin does indeed co-immunoprecipitate with WT survivin during mitosis, as does survivin11–142, but not with survivin1–120 (Fig. 4D). Finally, immunolocalisation in fixed cells revealed that borealin was misplaced in prometaphase and anaphase cells expressing only survivin1–120, but localized normally in cells expressing survivin11–142 (Fig. 4E).

In summary, the data herein presented suggest that the last 22 amino acids of survivin are required to bind to borealin and support mitosis and cytokinesis, whereas the first 10 amino acids are needed to protect cells from irradiation. How this short sequence contributes to protection from IR remains to be determined but initial data suggest that its removal may influence the rate of cell growth.

**Materials and Methods**

Unless otherwise stated, tissue culture reagents were obtained from www.lifetechnologies.com, and all other reagents were from www.sigmaaldrich.com.
Molecular biology

Survivin truncations were generated by PCR using VENT polymerase (www.neb.com), with wild type human survivin (accession number NM001168) in pBluescript as template, see.24,28 Once generated, mutants were subcloned into the mammalian expression vector pcDNA3.1 (Invitrogen) such that the protein was fused at its C-terminus to GFP. All final constructs were sequence verified prior to use.

Cell Lines, transfection and proliferation

HeLa cell lines stably expressing GFP, survivin-GFP, survivin1–120-GFP or survivin11–142-GFP were established by transfection with the relevant pcDNA3.1 constructs using Transit LT1 (www.mirusbio.com) diluted in Optimem, and selection post-transfection with 500 μg/ml G418, followed by clonal identification, pooling and FACS sorting on the GFP signal. Cells were cultured at 37°C and 5% CO2 in DMEM with 10% FCS. Control and survivin specific oligonucleotides (Ambion, www.lifetecnologies.com) diluted in OptiMEM were transfected into cells at a final concentration of 10 nM, using HiPerfect (www.qiagen.com), and cells allowed a minimum of 48 h to grow in antibiotic free medium before analysis. RNAi insensitive versions of survivin were made resistant to siRNA knockdown by a base substitution C54G (Wheatley et al., 2004).

Immunoblotting and immunoprecipitation

Cells were lysed in RIPA buffer (20mM Tris, pH8.0, 137 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1% Non-Idet P40, and 1% SDS) with protease and phosphatase inhibitors. Cell lysates were then boiled in Laemmli sample buffer, and 50 μg protein lysate loaded per lane. Proteins were separated by SDS-PAGE (12%) and transferred to 0.22 μm nitrocellulose (www.pall.com) using standard Tris/glycine based methods. The following antibodies were used: anti-survivin (in-house; 1/1000) and anti-tubulin (B512, 1/2000, Sigma, T5168). HRP-conjugated secondary antibodies (diluted 1/2000) were from www.dako.com. All antibodies were prepared in 5% milk (Marvel) in PBS with 0.1% Tween 20. Signals were detected using enhanced chemiluminescence and hyperfilm (www.gehealthcare.com).

Immunoprecipitation was carried out as described in,27 except that protein G Dynabeads (www.lifetecnologies.com) were used.

Caspase assay

Cells were seeded at 1×10^5 per well in 24-welled plates, and cultured for 16 h before induction of apoptosis. Cells were treated with 250 ng/ml recombinant TRAIL (www.peprotech.com cat no. 310–04) for the times indicated, then lysed in 200 μl of mammalian protein extraction reagent (MPER; www.pierce.com) containing 1 mM EDTA, 1 μg/μl pepstatin A, 1 mM AEBSF for 45 minutes. Caspase activity assays were performed in a 96-well microtiter plate: 4 μg of the caspase-3 substrate Ac-DEVD-AMC (Bioimol cat no. P-411, www.enzolifesciences.com) was incubated with 40 μl of cell lysate and 200 μl of reaction buffer (20 mM HEPES, 10% glycerol, 2 mM DTT, pH 7.5) at 37°C for 1 h. Fluorescent emission (450 nm) was measured using a Spectrofluorometer (Fluostar Galaxy, BMG Labtechnologies) with excitation wavelength set at 390 nm.

X-Irradiation and clonogenic survival Aasays

Cells were seeded at low density in 10 cm² Petri dishes and irradiated 2 h later at 0, 2.5, or 5 Grays using an Hs-X-ray System (A.G.O Installations Ltd). Seven days post-irradiation cultures were stained with 1% methylene blue in absolute ethanol (1 h, 25°C), and colonies of >50 cells counted.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgements

I would like to thank Mr. Jamie Webster and Ms. Elisa Marrelli for technical support. Thanks also to Jessica Thomas, Yanisa Jarusyingumedrong and Katrina Garcha for their assistance with experiments during their undergraduate dissertations.

References

1. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, et al. Analysis of human transcriptomes. Nat Gen 1999; 23:387-8; PMID:10581018; http://dx.doi.org/10.1038/97447

2. Altiery DC. Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer 2008; 8:61-70; PMID:18875512; http://dx.doi.org/10.1038/nrc2293

3. Guha M, Altiery DC. Survivin as a global target of intrinsic tumor suppression. Cell Cycle 2009; 8:2708-10; PMID:19717980; http://dx.doi.org/10.4161/cc.8.17.9457

4. Zaffaroni N, Pennati M, Daidone MG. Survivin as a global target for new anticancer interventions. J Cell Mol Med 2005; 9:360-72; PMID:15963255; http://dx.doi.org/10.1111/j.1582-4934.2005.00361.x

5. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7:602-8; PMID:10876248; http://dx.doi.org/10.1038/77929

6. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual α-helical extensions. Mol Cell 2000; 6:183-9; PMID:10940039; http://dx.doi.org/10.1016/S1097-2765(00)00019-8

7. Jayaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E. Structure of a survivin-borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell 2007; 131:271-85; PMID:17696729; http://dx.doi.org/10.1016/j.cell.2007.07.045

8. Kelly AE, Ghenoix C, Xue JZ, Zietzsch C, Kimura H, Funakaki H. Survivin Read: Phosphorylated Histone H3 Throneine 3 to Activate the Mitotic Kinase Aurora B. Science 2010; 330:235-9; PMID:20705815; http://dx.doi.org/10.1126/science.1189505

9. Colnaghi R, Connell CM, Barrett RMA, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 281:33450-6; PMID:16950794; http://dx.doi.org/10.1074/jbc.C600164200

10. Knauer SK, Bier C, Hambremich N, Stauber RH. The survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Reports 2006; 7:12159-65; PMID:17099693; http://dx.doi.org/10.1038/sjembr.7200824

11. Engdahl D, Rodriguez JA, Fish A, Giaccone G, Fornerod M. Homodimerization antagonizes nuclear export of survivin. Traffic 2007; 11:1495-502; PMID:17714426; http://dx.doi.org/10.1111/j.1600-0854.2007.00629.x

12. Connell CM, Colnaghi R, Wheatley SP. Nuclear survivin has reduced stability and is not cytoprotective. J Biological Chemistry 2008; 238:3289-96; PMID:16950794; http://dx.doi.org/10.1074/jbc.M704461200

13. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Rohe P, Nestler U, Song Q, Loeffler J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23:704-506; PMID:153266475; http://dx.doi.org/10.1038/sj.onc.1208049

14. Wheatley SP. Nuclear survivin: consequences and therapeutic implications. Advances in Cancer Therapy, InTech open 2011; Chapter 15:331-42

15. Wang HJ, Holloway MP, Ma L, Cooper ZA, Riedo M, Samkari A, Eleniota- Johnson KSJ, Chin YE, Altura RA. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010; 285:36129-37; PMID:20826784; http://dx.doi.org/10.1074/jbc.M110.152777

16. Ruchaud S, Carmena M, Ehrnawa WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8:798-812; PMID:17848966; http://dx.doi.org/10.1038/nrm2257

17. Vater G, Melkova R, Lens SMA. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 2006; 173:833-7; PMID:16796825; http://dx.doi.org/10.1083/jcb.200604032

18. Aljaberi A, Webster J, Wheatley S. Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancer. Cancer Cell Internat 2014; 14:78-85.

19. Wheatley SP, Carvalho A, Vagnarelli P, Ehrnawa WC. INCENP is required for proper targeting of survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol 2001; 11:886-90; PMID:11516652; http://dx.doi.org/10.1016/S0092-8648(01)0038-X

20. Petrovsky EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. A visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605-12; PMID:15264254

Funding

Imaging was performed in the Advanced Microscopy Unit, at the University of Nottingham with a DeltaVision Elite system funded by the Wellcome Trust (Award number WT094233MA).